Connection

Mark Kindy to Alzheimer Disease

This is a "connection" page, showing publications Mark Kindy has written about Alzheimer Disease.
Connection Strength

3.831
  1. Effects of GrandFusion Diet on Cognitive Impairment in Transgenic Mouse Model of Alzheimer's Disease. Nutrients. 2020 Dec 30; 13(1).
    View in: PubMed
    Score: 0.494
  2. GM6 Attenuates Alzheimer's Disease Pathology in APP Mice. Mol Neurobiol. 2019 Sep; 56(9):6386-6396.
    View in: PubMed
    Score: 0.435
  3. High-Sodium Diet Has Opposing Effects on?Mean Arterial Blood Pressure and?Cerebral Perfusion in a Transgenic Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2016 10 04; 54(3):1061-1072.
    View in: PubMed
    Score: 0.368
  4. Preface. Turk J Med Sci. 2015; 45(5):i-ii.
    View in: PubMed
    Score: 0.326
  5. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing A?PP containing the wild-type ?-secretase site sequence. J Alzheimers Dis. 2012; 29(4):827-40.
    View in: PubMed
    Score: 0.265
  6. The cysteine protease inhibitor, E64d, reduces brain amyloid-? and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, ?-secretase activity. J Alzheimers Dis. 2011; 26(2):387-408.
    View in: PubMed
    Score: 0.247
  7. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biol Chem. 2010 Aug; 391(8):861-72.
    View in: PubMed
    Score: 0.240
  8. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol. 2008 May; 172(5):1342-54.
    View in: PubMed
    Score: 0.205
  9. Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol Chem. 2007 Sep; 388(9):979-83.
    View in: PubMed
    Score: 0.196
  10. Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders. Pharmacol Rev. 2022 07; 74(3):600-629.
    View in: PubMed
    Score: 0.137
  11. Control of ?-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-?/? and Nuclear Factor ?-B. Curr Alzheimer Res. 2021; 18(12):941-955.
    View in: PubMed
    Score: 0.124
  12. CBF regulation in hypertension and Alzheimer's disease. Clin Exp Hypertens. 2020 Oct 02; 42(7):622-639.
    View in: PubMed
    Score: 0.118
  13. Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochim Biophys Acta. 2012 Jan; 1824(1):89-104.
    View in: PubMed
    Score: 0.065
  14. Targets for AD treatment: conflicting messages from ?-secretase inhibitors. J Neurochem. 2011 May; 117(3):359-74.
    View in: PubMed
    Score: 0.063
  15. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun. 2009 Aug 21; 386(2):284-8.
    View in: PubMed
    Score: 0.055
  16. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008 Mar 21; 283(12):7745-53.
    View in: PubMed
    Score: 0.050
  17. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol Chem. 2007 Feb; 388(2):247-52.
    View in: PubMed
    Score: 0.047
  18. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum Mol Genet. 2005 Feb 01; 14(3):447-60.
    View in: PubMed
    Score: 0.041
  19. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J. 2004 Oct 13; 23(20):4096-105.
    View in: PubMed
    Score: 0.040
  20. Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors. Curr Drug Targets. 2004 Aug; 5(6):517-28.
    View in: PubMed
    Score: 0.040
  21. Neprilysin regulates amyloid Beta peptide levels. J Mol Neurosci. 2004; 22(1-2):5-11.
    View in: PubMed
    Score: 0.038
  22. Abeta deposition is essential to AD neuropathology. J Alzheimers Dis. 2002 Jun; 4(3):133-8.
    View in: PubMed
    Score: 0.034
  23. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis. 2002 Jun; 4(3):145-54.
    View in: PubMed
    Score: 0.034
  24. Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res. 2002 Jan 04; 924(1):90-7.
    View in: PubMed
    Score: 0.033
  25. Vulnerability of synaptosomes from apoE knock-out mice to structural and oxidative modifications induced by A beta(1-40): implications for Alzheimer's disease. Biochemistry. 2001 Feb 27; 40(8):2548-54.
    View in: PubMed
    Score: 0.031
  26. Presenilin-1 mutation increases neuronal vulnerability to focal ischemia in vivo and to hypoxia and glucose deprivation in cell culture: involvement of perturbed calcium homeostasis. J Neurosci. 2000 Feb 15; 20(4):1358-64.
    View in: PubMed
    Score: 0.029
  27. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology. 1999 Oct 22; 53(7):1391-6.
    View in: PubMed
    Score: 0.028
  28. Brain pyroglutamate amyloid-? is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. J Alzheimers Dis. 2014; 41(1):129-49.
    View in: PubMed
    Score: 0.019
  29. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem. 2008 Jul; 106(1):475-85.
    View in: PubMed
    Score: 0.013
  30. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci. 2003 Mar 15; 23(6):1992-6.
    View in: PubMed
    Score: 0.009
  31. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun. 1996 Sep 24; 226(3):672-80.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.